A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang… - Nature medicine, 2019 - nature.com
B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …
被引用次数：468 相关文章

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He… - Nature …, 2019 - scholars.uthscsa.edu
B-cell lymphoma extra large (BCL-X L) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as …

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He… - Nature …, 2019 - mdanderson.elsevierpure.com
B-cell lymphoma extra large (BCL-X L) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as …

A selective BCL-X. sub. L PROTAC degrader achieves safe and potent antitumor activity.

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang… - Nature Medicine, 2019 - go.gale.com
B-cell lymphoma extra large (BCL-X. sub. L) is a well-validated cancer target. However, the
on-target and dose-limiting thrombocytopenia limits the use of BCL-X. sub. L inhibitors, such …

[引用][C] A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang… - Nature Medicine, 2019 - cir.nii.ac.jp
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 …

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang… - Nature …, 2019 - europepmc.org
Abstract BCL-X L is a well-validated cancer target. However, the on-target and dose-limiting
thrombocytopenia limits the use of BCL-X L inhibitors such as ABT263 as safe and effective …

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He… - Nature …, 2019 - pubmed.ncbi.nlm.nih.gov
B-cell lymphoma extra large (BCL-X L) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as …

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He… - Nature …, 2019 - ohiostate.elsevierpure.com
B-cell lymphoma extra large (BCL-X L) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-X L inhibitors, such as …
[HTML] nih.gov

[HTML][HTML] A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang… - Nature …, 2019 - ncbi.nlm.nih.gov
Abstract BCL-X L is a well-validated cancer target. However, the on-target and dose-limiting
thrombocytopenia limits the use of BCL-X L inhibitors such as ABT263 as safe and effective …

A selective BCL-X L PROTAC degrader achieves safe and potent antitumor activity

S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu… - paper.sciencenet.cn
B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-
target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as …